全文获取类型
收费全文 | 5578篇 |
免费 | 299篇 |
国内免费 | 87篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 44篇 |
妇产科学 | 31篇 |
基础医学 | 543篇 |
口腔科学 | 59篇 |
临床医学 | 332篇 |
内科学 | 1834篇 |
皮肤病学 | 73篇 |
神经病学 | 377篇 |
特种医学 | 218篇 |
外科学 | 977篇 |
综合类 | 9篇 |
预防医学 | 110篇 |
眼科学 | 93篇 |
药学 | 315篇 |
中国医学 | 19篇 |
肿瘤学 | 878篇 |
出版年
2024年 | 2篇 |
2023年 | 40篇 |
2022年 | 67篇 |
2021年 | 140篇 |
2020年 | 75篇 |
2019年 | 130篇 |
2018年 | 140篇 |
2017年 | 139篇 |
2016年 | 145篇 |
2015年 | 155篇 |
2014年 | 209篇 |
2013年 | 212篇 |
2012年 | 398篇 |
2011年 | 430篇 |
2010年 | 292篇 |
2009年 | 203篇 |
2008年 | 365篇 |
2007年 | 340篇 |
2006年 | 383篇 |
2005年 | 388篇 |
2004年 | 335篇 |
2003年 | 344篇 |
2002年 | 359篇 |
2001年 | 66篇 |
2000年 | 60篇 |
1999年 | 55篇 |
1998年 | 81篇 |
1997年 | 53篇 |
1996年 | 50篇 |
1995年 | 59篇 |
1994年 | 40篇 |
1993年 | 36篇 |
1992年 | 25篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 17篇 |
1988年 | 20篇 |
1987年 | 11篇 |
1986年 | 5篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 9篇 |
1980年 | 10篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1969年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有5964条查询结果,搜索用时 0 毫秒
51.
Toshihiko Kotake Tsuneharu Miki Hideyuki Akaza Yoshinobu Kubota Yasunori Nishio Yosuke Matsumura Kazuo Ota Nobuya Ogawa 《Cancer chemotherapy and pharmacology》1991,27(4):253-257
Summary The effects of recombinant granulocyte colony-stimulating factor (rG-CSF) on the myelosuppression, especially neutropenia, induced by cancer chemotherapy in patients with urogenital cancer were investigated in a randomized, controlled clinical study. In this study, rG-CSF was given subcutaneously at a dose of 2 g/kg per day for 14 consecutive days. Changes in neutrophil counts were compared between the first (no rG-CSF) and second cycles (rG-CSF treatment period) of chemotherapy. rG-CSF administration was found to be effective in reducing the duration of neutropenia, in elevating the neutrophil nadir, and in reducing recovery time. Based on comparisons between the randomized rG-CSF treatment group (with rG-CSF) and the control group, treatment with rG-CSF resulted in the moderation or prevention of neutropenia and the acceleration of recovery. These results demonstrate that in chemotherapy of patients with urogenital cancer, in which neutropenia is a dose- or schedule-limiting factor, the concomitant use of rG-CSF may enable an increase in the dose (higher single dose or increased dose per unit of time) or shorten the chemotherapy period. 相似文献
52.
More than 10 years of follow-up of two patients after total femur replacement for malignant bone tumor 总被引:2,自引:0,他引:2
Nakamura S Kusuzaki K Murata H Takeshita H Hirata M Hashiguchi S Hirasawa Y 《International orthopaedics》2000,24(3):176-178
One patient with osteosarcoma and one with Ewing’s sarcoma of the femur were in 1987 and 1988 treated with prosthetic replacement
of the femur and chemotherapy. There has been no loosening of the prostheses and no recurrence of the tumor. The patients
have maintained 60% and 63% limb function scores evaluated by ISOLS criteria.
Accepted: 17 March 2000 相似文献
Résumé Deux patients, l’un avec un ostéosarcome, l’autre avec un sarcome d’EWING, furent opérés en 1987–1988 avec remplacement prothétique du fémur, associéà une chimiothérapie. Ces patients ont été suivis sans qu’il soit noté de récidive. Il n’y a pas de descellement, ni de luxation de la prothèse. Un score fonctionnel évalué selon les critères de l’ISOLS, montre une conservation de 60% et 63% de la fonction du membre inférieur.
Accepted: 17 March 2000 相似文献
53.
54.
Hiroaki Kondo Hiroeki Sahara Akihiro Miyazaki Yuki Nabeta Yoshihiko Hirohashi Takayuki Kanaseki Akira Yamaguchi Naoyuki Yamada Kazuo Hirayama Manabu Suzuki Junji Hamuro Toshihiko Torigoe Nobuaki Takahashi Gen-iku Kohama Hideyuki Ikeda Noriyuki Sato 《Cancer science》2002,93(8):917-924
A large number of human tumor antigens recognized by CD8+ cytotoxic T lymphocytes (CTL) have been identified. Some of them have been employed in clinical trials and have achieved some objective responses. However, little is known about those that are recognized by CD4+ T cells, except for a very few that were identified from melanomas. Previously, we reported that an oral squamous cell carcinoma (SCC) cell line, OSC–20, was effectively lysed by HLA-DRB1·08032 (HLA-DRS)-restricted autologous CD4+ T cell line, TcOSC–20. In this study, we performed two steps of chromatographic purification of the tumor cell lysate in combination with mass spectrometry. We found one reverse-phase high-performance liquid chromatography (RP-HPLC) fraction that was effectively recognized by the T cells. We analyzed the fraction by nano-liquid chromatography/electrospray ionization ion trap mass spectrometry (LC/MS/MS) and found six representative ions. We could determine the primary amino acid sequence of each of the six ions. Three of them contained a potential HLA-DR8 binding motif, and TcOSC–20 showed a rather strong cytotoxic response to one of the synthetic pep tides, namely, amino acid residues 321–336 of human a-enolase. Thus, several gene products of squamous cancer cells are endogenously processed and may be presented on HLA class II molecules, so that they could constitute target molecules for autologous CD4+ T cells. 相似文献
55.
Ken Kamisawa Takeo Kosaka Kohei Nakamura Yota Yasumizu Hiroshi Hongo Toshikazu Takeda Kazuhiro Matsumoto Hiroshi Nishihara Mototsugu Oya 《Cancer science》2022,113(9):3161
The purpose of this study was to investigate factors predicting the sensitivity to cabazitaxel therapy in metastatic castration‐resistant prostate cancer (mCRPC) patients with phosphatase and tensin homolog deleted from chromosome 10 (PTEN) alterations. This single‐institution, retrospective study included 12 mCRPC patients with PTEN alterations who had received cabazitaxel therapy. Five patients (41%) responded to cabazitaxel therapy with a prostate‐specific antigen (PSA) level decline of ≥30% from baseline, and all of them had responded to prior docetaxel therapy with a PSA decline of ≥30%. None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. Of the seven patients who did not respond to cabazitaxel and whose PSA declined from baseline was <30%, five (71%) were also refractory to prior docetaxel therapy. The PSA responses to docetaxel and cabazitaxel were significantly correlated (p = 0.027). Kaplan–Meier analysis revealed that progression‐free survival (PFS) for cabazitaxel was significantly shorter for prior docetaxel nonresponders (3.3 versus 9.1 months, p = 0.028). Multivariate analysis revealed that a poor response to prior docetaxel (PSA decline < 30%) (hazard ratio [HR] = 6.382, 95% confidence interval [CI] 1.172–34.750, p = 0.032) and baseline PSA of ≥20 ng/ml (HR = 33.584, 95% CI 2.332–483.671, p = 0.010) were independent prognostic factors for PFS with cabazitaxel therapy. These results demonstrate cross‐resistance between docetaxel and cabazitaxel. The response to prior docetaxel therapy can influence the sensitivity to cabazitaxel therapy in mCRPC patients with PTEN alterations. 相似文献
56.
A novel dimeric flavonol glycoside linked through a methylene group, kunzeagin A (1), and six new chromone C-glucosides, kunzeachromones A-F (2-7), were isolated along with seven known compounds from the leaf extract of Kunzea ambigua. The structures of these compounds were elucidated on the basis of spectroscopic analyses and chemical properties. Kunzeachromones A-F provided additional examples of galloylated C-glucosidic chromones occurring in the Myrtaceae. Kunzeagin A (1) and major constituents of this plant (6-C- and 8-C-glucosylchromones and their monogallates) exhibited potent inhibitory effects on activation of Epstein-Barr virus early antigen induced by 12-O-tetradecanoylphorbol 13-acetate in Raji cells. 相似文献
57.
Shunsuke Ogata Yoshito Ishii Keiichiro Asano Erena Kobayashi Shun Kubota Keita Takahashi Yosuke Miyaji Yuichi Higashiyama Hideto Joki Hiroshi Doi Michiaki Koga Hideyuki Takeuchi Fumiaki Tanaka 《Internal medicine (Tokyo, Japan)》2022,61(11):1757
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia. 相似文献
58.
Takahashi N Nimura H Aoki H Koyama T Mitsumori N Aiba K Kashiwagi H Yanaga K 《Chemotherapy》2007,53(5):378-382
We report 2 cases of advanced gastric cancer with synchronous liver metastases who were successfully downstaged using S-1 plus low-dose cisplatin chemotherapy followed by surgical resection. S-1 was administered orally (80 mg/m(2)/day) twice daily for 14 consecutive days, and cisplatin (15 mg/m(2)) was infused over 1 h on days 1 and 8. Successful downstaging of the hepatic metastases was confirmed by imaging analyses; however, neither patient showed a complete response of the primary lesion in the stomach. Toxicities, according to the WHO criteria, were mild. The patients underwent surgical resection within 4 weeks after the last chemotherapy. Postoperatively, they were discharged without complications and received adjuvant chemotherapy. Both patients remained alive and well at 17 and 12 months after surgery, respectively, without recurrence. These cases provide further evidence that S-1 plus low-dose cisplatin chemotherapy enables downstaging of advanced gastric cancer and a subsequent potentially curative resection without serious complications. 相似文献
59.
60.